Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OmniLytics has entered into a collaborative research and license agreement with Elanco, a division of Eli Lilly and Company. The agreement encompasses a series of products for the treatment of food-borne bacterial pathogens using OmniLytics's bacteriophage technology.
Subscribe to our email newsletter
The companies will focus on phage-based products that could help the animal health and food production industries in their struggle to control outbreaks of human pathogenic bacteria such as E coli, Salmonella and Listeria, and the numerous cases of human illness associated with them.
Justin Reber, president and CEO of OmniLytics, said: “The synergies gained through our combined resources have created an exciting partnership by combining the phage expertise of OmniLytics with the product development, market understanding, sales channel, brand and reach of Elanco.”